A new modified schedule of sunitinib for metastatic renal cell carcinoma: A retrospective analysis

Acta Biomedica

Volumn 83, Issue 2, 2012, Pages 88-94

  Buti, Sebastiano ^a,b   Donini, Maddalena ^a   Lazzarelli, Silvia ^a   Passalacqua, Rodolfo ^a  

^a Oncology Division   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Dose intensity; Modified; Renal cell carcinoma; Schedule; Sunitinib

Indexed keywords

EVEROLIMUS; SUNITINIB; SYTENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY METASTASIS; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; PATIENT COMPLIANCE; PAUSE SYMPTOM; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SYMPTOM; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874082452     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
2. Gkountouvas A, Kostoglou-Athanassiou I, Veniou E, Repousis P, Ziras N, Kaldrimidis P. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer. Thyroid 2010; 20: 597-600.
3. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-6.
4. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-6.
5. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferonalfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
8. Houk BE, Bello CL, Kang D, Amantea MA. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-506.
9. Porta C, Szczylik C, Bracarda S, et al. Short-and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26: May 20 suppl; abstr 5114.
10. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26: May 20 suppl; abstr 5024.
11. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationsheep between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodinamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357-71.
12. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2000; 9: 327-37.
13. Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010; 40: 194-202.
14. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-45.
15. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2: 1011-21.
16. Motzer RJ, Hutson T, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol 2011; 29:suppl 7; abstr LBA308.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
18. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96.
19. Buti S, Lazzarelli S, Chiesa MD, et al. Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study. J Immunother 2010; 33: 735-41.
20. Vázquez S, León L, Fernández O, Lázaro M, Grande E, Aparicio L. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Ther 2012; 29:202-217. doi: 10.1007/s12325-011-0099-9. Epub 2012 Feb 7.
21. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-16.
22. Suarez C, Rini BI. Determining the optimal dose and schedule of sunitinib. Some answers, more questions. Cancer 2012; 118: 1178-80.
23. Ravaud A, Bello CL. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. Anticancer Drugs 2011; 22: 377-83.